OncoZenge AB (publ) (ONCOZ.ST)

SEK 3.97

(4.34%)

Market Cap (In SEK)

46.44 Million

Revenue (In SEK)

3000.00

Net Income (In SEK)

-15.9 Million

Avg. Volume

40.11 Thousand

Currency
SEK
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
2.62-12.1
PE
-
EPS
-
Beta Value
1.158
ISIN
SE0015504097
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Stian Kildal
Employee Count
-
Website
https://www.oncozenge.se
Ipo Date
2021-02-12
Details
OncoZenge AB (publ), a pharmaceutical company, develops healthcare products for cancer supportive care. It offers BupiZenge, which has completed Phase 2 clinical trial for the treatment of oral mucositis. The company was founded in 2020 and is headquartered in Bromma, Sweden. OncoZenge AB (publ) is a subsidiary of Moberg Pharma AB (publ).